{"name":"Zhimin Shao","slug":"zhimin-shao","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5WY2tJYTBlVGRlZWQyZll4dUpoZEw4QjdTVGNoRkwxY1pVTHFuSGNHR29NOWVzaUxBOF9BakJKbUlodlI3U1JRNHpMczE1bUZkYlY3bi1IUndsblRmTlV3?oc=5","date":"2025-01-21","type":"pipeline","source":"Nature","summary":"Pembrolizumab and chemotherapy in high-risk, early-stage, ER - Nature","headline":"Pembrolizumab and chemotherapy in high-risk, early-stage, ER","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE5jaVpzZzY0UjUtOW00elo0dWNfTHBmMlJSTUJIcHV1WnF4U2N4b1B6M21nODVuaVo2WkNiR3pmMWNLRC1ncXBFdEZtWllBVGlwZHJIZEZLa3oyZy12RVN4Q0EyYUI4dkNRemI2bjRjdXY2THhJV1J1bVF2WnZQZw?oc=5","date":"2024-12-19","type":"pipeline","source":"China Daily","summary":"Shanghai expert devises new treatment for aggressive breast cancer - China Daily","headline":"Shanghai expert devises new treatment for aggressive breast cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE9fVmhfQktScU9iUG9LQmYxRnBPaG5IalpPRnBIQWR5UEJBQl9tUHVQRUpncWw2ZlphZVkwbGlDNUg2OEpzZS01X2NUMVB0UkRVdHV5emx2cGNqUUhJYXF5UnpOVDRsSGM1?oc=5","date":"2024-08-13","type":"trial","source":"Wiley Online Library","summary":"Initial ribociclib plus endocrine therapy for HR+/HER2− advanced breast cancer in pre‐ and postmenopausal Chinese women: Primary results from a phase 2 randomized study - Shao - 2024 - Cancer Medicine","headline":"Initial ribociclib plus endocrine therapy for HR+/HER2− advanced breast cancer in pre‐ and postmenopausal Chinese women:","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBQYVdvYmlQRVcwd0hnU1pLbHNqZWRRLXhIUkFrUjFURWdLN3pPalVMbW12aXgtMXVVVFVic2JjejNtb2kxWDRiMU0tRXpnWFh1alRKQVZ3b1Z6am1PV1d3?oc=5","date":"2024-06-21","type":"patent","source":"Nature","summary":"QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multice","headline":"QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for H","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE4teHhzVmI3MEJGRmFzZWdmUF9jNXZNQjkzbjRuM0YtT2ltMXpINWxXLThjWm1WUXcwRDhvdnROUWdScnlBNlRpUVVxRzFCUzFmVUZnaWFoYldNb3pvUkZ4SFZMLThQMDNNSkE?oc=5","date":"2019-04-19","type":"pipeline","source":"Wiley Online Library","summary":"Fulvestrant in the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: A review - Wiley Online Library","headline":"Fulvestrant in the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced bre","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}